Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's second consecutive day of losses.

Barclays has recently reduced Vertex Pharmaceuticals Incorporated (VRTX) stock to Equal Weight rating, as announced on August 5, 2024, according to Finviz. Earlier, on June 27, 2024, Redburn Atlantic ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report) on September 13 and set a price ...

The "Gene Editing Therapeutics Market" report has been added to ResearchAndMarkets.com's offering.The gene editing therapeutics market is estimated to be $11 million in 2024 and is forecasted to grow ...

CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other biotech stocks. As we have mentioned in our article, “10 Best ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an average annual return of 21.14%. Currently, Vertex Pharmaceuticals has ...

In a recent transaction, Jeffrey M. Leiden, the Executive Chairman of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), sold 3,784 shares of company stock. The transaction, dated August 30, 2024, was carried ...